Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.58 |
| ▸ | MAPT | P10636 | 9/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | THRB | P10828 | 1/20 | 0.53 |
| ▸ | TP53 | P04637 | 2/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | S1PR1 | P21453 | 4/20 | 0.48 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20116262 | 0.88 | MAPT (0.59) | SMN1; SMN2MAPTGAAMAPK1THRB | |
| SCHEMBL20116655 | 0.88 | SMN1; SMN2 (0.54) | SMN1; SMN2MAPTGAAMAPK1THRB | |
| SCHEMBL20117011 | 0.87 | MAPT (0.61) | SMN1; SMN2MAPTGAAMAPK1THRB | |
| SCHEMBL22343934 | 0.87 | SMN1; SMN2 (0.60) | SMN1; SMN2MAPTGAAMAPK1THRB | |
| SCHEMBL26998415 | 0.86 | MAPT (0.53) | SMN1; SMN2MAPTGAAMAPK1THRB | |
| SCHEMBL20116601 | 0.83 | MAPT (0.57) | SMN1; SMN2MAPTMAPK1THRBTP53 | |
| SCHEMBL20116135 | 0.77 | MAPT (0.53) | SMN1; SMN2MAPTTHRBTP53ALDH1A1 | |
| SCHEMBL22358093 | 0.76 | MAPT (0.51) | SMN1; SMN2MAPTMAPK1THRBTP53 | |
| SCHEMBL22358160 | 0.76 | MAPT (0.51) | SMN1; SMN2MAPTMAPK1THRBTP53 | |
| SCHEMBL20116633 | 0.76 | MAPT (0.51) | SMN1; SMN2MAPTMAPK1THRBTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11873298-B2 | Compounds and uses thereof | JANSSEN PHARMACEUTICA NV (BE) | 2024-01-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11873298-B2 | Compounds and uses thereof | NLN, ACHE, CLN6 | SMN1; SMN2 13/4885MAPT 22/4885GAA 67/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.